Nascent Pharma Holdings (NASC) AI Stock Analysis

• Market Cap: $1.25M
• Dividend Yield: N/A
• Average Volume (3M): 35.25K
• Price to Earnings (P/E): ―
• Beta (1Y): -1.42
• Revenue Growth: N/A
• EPS Growth: N/A
• Country: US
• Employees: 12
• Sector: Healthcare
• Sector Strength: 45
• Industry: Drug Manufacturers - Specialty & Generic
• EPS (TTM): N/A
• Shares Outstanding: 75,841,990
• 10 Day Avg. Volume: 42,355
• 30 Day Avg. Volume: 35,253
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• P/FCF Ratio: N/A
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 30 Underperform
• Price Target: ―

Can B's overall score reflects significant financial struggles, including negative profitability and liquidity issues. Technical analysis shows some long-term stability but short-term weakness. The company's valuation metrics are poor, with negative earnings and no dividend yield, highlighting substantial risks.

Nascent Pharma Holdings Business Overview & Revenue Model

Company Description

Can B Corp (CANB) is a health and wellness company focused on developing and marketing hemp-derived products, including CBD oils, topicals, and other related products. The company operates in the nutraceutical and medical sectors, providing consumers with alternative health solutions aimed at promoting overall well-being. Can B Corp combines innovation with high-quality sourcing to offer a diverse range of products that cater to the growing demand for natural health supplements.

How the Company Makes Money

Can B Corp generates revenue primarily through the sale of its hemp-derived products, which are distributed both through direct-to-consumer channels and wholesale distribution networks. The company leverages e-commerce platforms to reach a broad customer base and enhance its market presence. Key revenue streams include the sale of CBD oils, topicals, and other hemp-based wellness products. Can B Corp also capitalizes on strategic partnerships with retailers and distributors to expand its reach in various markets. Additionally, the company may engage in private label and white label manufacturing for other brands, providing another avenue for revenue generation. Factors contributing to its earnings include the growing consumer interest in natural health alternatives and the legalization and increasing acceptance of hemp-derived products in various regions.

Nascent Pharma Holdings Financial Statement Overview

Summary

Income Statement

Balance Sheet

Cash Flow

Breakdown
Income Statement
Total Revenue
Gross Profit
EBITDA
Net Income
Balance Sheet
Total Assets
Cash, Cash Equivalents and Short-Term Investments
Total Debt
Total Liabilities
Stockholders Equity
Cash Flow
Free Cash Flow
Operating Cash Flow
Investing Cash Flow
Financing Cash Flow

Nascent Pharma Holdings Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 0.02
• 50DMA: Negative
• 100DMA: Positive
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For NASC, the sentiment is Neutral. The current price of 0.02 is below the 20-day moving average (MA) of 0.02, below the 50-day MA of 0.02, and below the 200-day MA of 0.03, indicating a bearish trend. The MACD of >-0.01 indicates Negative momentum. The RSI at 45.49 is Neutral, neither overbought nor oversold. The STOCH value of 60.71 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for NASC.

Nascent Pharma Holdings Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
UPC	51 Neutral	$2.41M	―	2.66%	―	-27.81%	―
CPHI	41 Neutral	$5.07M	-1.03	-52.05%	―	-29.64%	73.63%
RDHL	38 Underperform	$3.60M	―	―	―	―	―
PRFX	34 Underperform	$2.11M	>-0.01	―	―	―	―
SHPH	32 Underperform	$3.09M	―	-551.04%	―	―	31.53%
NASC	30 Underperform	$1.25M	-0.05	―	―	―	―